Increased cortical kynurenate content in schizophrenia.

By R. Schwarcz, A. Rassoulpour, H. Wu, D. Medoff, C. Tamminga, R. Roberts. Biological Psychiatry, 2001

594 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Autism‐like behavioral phenotypes in BTBR T+tf/J mice (2008, background): “Unusual levels of kynurenic acid have been implicated in other neuropsychiatric diseases including schizophrenia and Huntington’s disease (Sapko et al. 2006; Schwarcz et al. 2001).”
The Brain Metabolite Kynurenic Acid Inhibits α7 Nicotinic Receptor Activity and Increases Non-α7 Nicotinic Receptor Expression: Physiopathological Implications (2001, background): “…levels are increased in patients with Alzheimer’s disease (AD) (Baran et al., 1999), Down’s syndrome (DS) (Baran et al., 1996), and schizophrenia (Schwarcz et al., 2001), and levels are decreased in patients with end-stage Parkinson’s disease (PD) (Ogawa et al., 1992) and Huntington’s disease…”
Mammalian Nicotinic Acetylcholine Receptors: From Structure to Function (2009, background): “Since KYNA levels are significantly elevated in the brain of individuals with AD (49) and schizophrenia (420), it is possible that the antagonism of KYNA-induced inhibition of 7 nAChRs may be causally related to the effectiveness of galantamine in these catastrophic disorders.”